ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that it has signed a term sheet with Lee’s Pharmaceutical (HK) Limited, headquartered in Hong Kong, for the license of Thymosin Beta 4-based products, including the Company’s RGN-259, RGN-352 and RGN-137 product candidates, in China, Hong Kong and Macau. Lee’s shall pay RegeneRx $200,000 upon signing of the term sheet, and will pay RegeneRx an additional $200,000 upon signing of the definitive license agreement, which RegeneRx expects to occur within 30 – 60 days.
